Latest News

According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.

According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.

According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...

According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.

According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with...

According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...

The TNBC-DX, a novel genomic test for patients with early-stage triple-negative breast cancer, was found to be effective at predicting a patient’s pCR and survival outcomes.

According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...

A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.